Drugs / NIR178
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04237649 | Feb 2020 → Sep 2023 | cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 13 trials | ||||||
| Phase 1 | NCT04895748 | Nov 2021 → Feb 2026 | clear cell renal carcinoma | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03742349 | Jan 2019 → Feb 2023 | triple-negative breast carcinoma | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03549000 | Jul 2018 → Oct 2022 | colorectal cancer, non-small cell lung carcinoma, ovarian cancer, pancreatic ductal adenocarcinoma +3 | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03207867 | Aug 2017 → Feb 2023 | colorectal cancer, diffuse large B-cell lymphoma, head and neck cancer, malignant pancreatic neoplasm +6 | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NIR178 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03549000 ↗ |
| Action | Inhibit | “NIR178, a new, non-xanthine based compound, is a potent oral adenosine A2a receptor against antagonist being developed by Novartis.” NCT03207867 ↗ |
| Route | Oral | “NIR178 was administered orally twice daily (BID) as a capsule” NCT03207867 ↗ |